AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.

The ROSY-F roll-over study from AstraZeneca (AZN) aims to keep patients on benralizumab (Fasenra) if they finished an earlier trial and still benefit from treatment. It focuses on people with severe asthma and related eosinophilic diseases and tracks long-term safety, giving investors a view on how durable and scalable this franchise may be.

The study tests benralizumab, a biologic drug given as a subcutaneous injection and already marketed as Fasenra. The goal is to maintain symptom control for responders while checking how well patients tolerate ongoing use in real-world style conditions.

ROSY-F is an interventional, Phase 3 roll-over study with a single treatment group and no placebo arm. There is no blinding, so both doctors and patients know they are receiving benralizumab, and the main aim is treatment support and safety follow-up rather than direct comparison.

The trial is listed as not yet recruiting, with initial submission on 17 February 2026, marking the formal setup stage. The latest update on 7 April 2026 signals that planning and regulatory steps are active, while primary and final completion dates are still ahead and will shape future label and lifecycle decisions.

For investors, this update underlines AstraZeneca’s push to extend the life of Fasenra in asthma and niche eosinophilic segments. Continued-investment messaging may support AZN’s valuation in respiratory versus rivals like GSK and Sanofi, as steady long-term safety data can help defend share and support pricing in a crowded biologics market.

The ROSY-F study is active in setup and remains ongoing on the registry, with further details and any future updates available on the ClinicalTrials portal.

To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.